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the fact that tumors do not exist independently of the host organism; cancer cells grow in the
context of a complexmicroenvironment composed of stromal cells, vasculature, and elements
of the immune system. As the antitumor effect of radiotherapy depends in part on the immune
system, and myeloid-derived cells in the tumor microenvironment modulate the immune
response to tumors, it follows that understanding the effect of radiation onmyeloid cells in the
tumor is likely to be essential for comprehending the antitumor effects of radiotherapy. In this
review, we describe the phenotype and function of thesemyeloid-derived cells, and stress the
complexity of studying this important cell compartment owing to its intrinsic plasticity. With
regard to the response to radiation of myeloid cells in the tumor, evidence has emerged
demonstrating that it is both model and dose dependent. Deciphering the effects of myeloid-
derived cells in tumors, particularly in irradiated tumors, is key for attempting to pharmaco-
logically modulate their actions in the clinic as part of cancer therapy.
Semin Radiat Oncol 25:18-27C 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Tumors are not merely a collection of cancer cells, ratherthey function more like an organ comprising a complex
and organized scaffolding of cellular and noncellular stroma
and recruited cells.1,2 The primary elements of the tumor
stroma are ﬁbroblasts and the noncellular collagen-rich
extracellular matrix they produce, the endothelial cells and
pericytes of the tumor vasculature, and resident leukocytes
such as macrophages driving progression. Tumors also recruit
inﬂammatory immune cells, including tumor-inﬁltrating lym-
phocytes (TILs, both CD4þ and CD8þ), natural killer (NK)
cells, NKT-cells, B cells, and an array ofmyeloid-derived cells.3
The various components of the microenvironment interact to
inﬂuence the growth and function of each of the other
elements, including the cancer cells themselves, mediatedg/10.1016/j.semradonc.2014.07.008
2015 The Authors. Published by Elsevier Inc. This is an open
ommons.org/licenses/by-nc-nd/3.0/).
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Myeloid-derived cells are an important part of the micro-
environment, both numerically and functionally, and play a
central role in regulating the antitumor immune response.3-5
Arising from the common myeloid progenitor cell, these
include tumor-associatedmacrophages (TAMs), dendritic cells
(DCs), polymorphonuclear neutrophils (PMNs), andmyeloid-
derived suppressor cells (MDSCs). Although each of these is
usually considered distinct populations, the functional dis-
tinctions in the tumor microenvironment can be somewhat
artiﬁcial.6 Rather, myeloid cells in tumors exist along a
spectrum of maturation and a plastic immunomodulatory
phenotype that can be inﬂuenced by ionizing radiation and
other exogenous agents.7-10
Functionally, myeloid cells are both friend and foe to the
antitumor immune response. They are essential for facilitating
antitumor immunity, but they take on an immunosuppressive
phenotype in established tumors, helping to promote immune
evasion.11 For example, DCs are necessary for cross-priming of
cytotoxic CD8þ T lymphocytes against tumor-speciﬁc anti-
gens and are required for immune-mediated rejection in
murine tumor models.12-14 However, tumor-resident DCs
often have a regulatory phenotype and express low levels of
costimulatory molecules and proinﬂammatory cytokines,
leading to T-cell anergy and tolerance.1,2,15-18 Similarly,access article under the CC BY-NC-ND license
Myeloid-Derived Cells in Tumors 19macrophages can promote immune effector function, yet
TAMs usually have an immunosuppressive phenotype that
promotes tumor growth, invasion, and metastasis.3,19-22
The fact that myeloid-derived cells contribute to an immu-
nosuppressive tumor microenvironment is no accident. Most
tumors evolve in the context of a competent immune system that
recognizes neoplastic cells by the expression of tumor-speciﬁc
neoantigens and embryonic antigens normally expressed exclu-
sivelyduringdevelopment. Tumors canonly growafter selection
of immune escape variants by immunoediting, and clinically
apparent tumors have undergone this process, developing the
means to escape immune recognition.3-5,23-25 Myeloid-derived
cells are at the center of immune escape. They are actively
recruited by tumor-secreted factors and maintained in an
immunosuppressive phenotype that allows for tumor growth
in the context of an otherwise competent immune system.5,6,8Phenotype and Function of
Myeloid-Derived Cells in the
Tumor Microenvironment
Macrophages
Macrophages are large mononuclear phagocytes that ingest
cellular debris, promote wound healing, and modify the localM
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macrophages develop from monocytes recruited from the
blood. They have tremendous tissue-speciﬁc phenotypic vari-
ability, and although there is no single set of macrophage-
speciﬁc surface markers, useful markers include the general
myeloid-lineage marker CD11b and F4/80 (in mice) and
CD14 and CD68 (in humans). Functional classiﬁcation of
macrophages as classically activated (M1) vs alternatively
activated (M2) is a useful and commonly used paradigm to
describe the extremes of a spectrum ofmacrophage phenotype
based on patterns of gene expression and cytokine produc-
tion8-11,28,29 (Fig. 1). M1 polarization develops in response to
inﬂammatory stimuli, such as interferon (IFN)-γ and lip-
opolysaccharide, and is characterized by higher surface
expression of major histocompatibility complex (MHC) Class
II and CD86. These M1 cells generate nitric oxide (NO)
catalyzed from arginine by inducible NO synthase (iNOS),
signal through STAT3 and STAT1, can kill tumor cells directly,
and stimulate antitumor T-cells by secreting the proinﬂamma-
tory cytokines IL-12 and IL-6. Conversely, in the presence of
IL-4 and IL-13 macrophages develops an M2 phenotype,
which suppress antitumor immunity by producing arginase
and the cytokines transforming growth factor (TGF)-β and
IL-10. M2 cells can be further identiﬁed by STAT6 phosphor-
ylation and surface expression of mannose receptor (CD206),
programmeddeath ligand2 (PD-L2), and restin-likemolecule-a.RegDCDC
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R.E. Vatner and S.C. Formenti20Macrophages in established tumors are usually M2 polar-
ized, suppressing antitumor immunity and directly promoting
tumor growth, invasion, and metastasis. TAMs are driven to
adopt this phenotype by factors secreted by cancer cells and
TILs, including tumor necrosis factor (TNF), prostaglandins,
and IL-10.11,22,30 Various mechanisms to explain this immu-
nosuppression have been proposed, most of which are shared
by MDSCs. Gabrilovich et al30 neatly parses these into 4
categories: (1) nutrient depletion, (2) oxidative stress, (3)
impairment of lymphocyte trafﬁcking and viability, and (4)
promotion of Treg numbers and function. T-cells depend on
certain nutrients such as the amino acid L-arginine for normal
growth and function, and arginase production by TAMs can
suppress antitumor immunity by modifying the metabolic
milieu of the tumor microenvironment. Arginase depletes
L-arginine and results in suppression of the effector activity of
TILs through downregulation of the expression of zeta chain of
the T-cell receptor (TCR) and progression through the cell
cycle.12-18,31-35
Another immunosuppressive mechanism used by both
TAMs (and MDSCs) is the generation of reactive oxygen
species (ROS).36-39 These ROS can modify the structure of
both theMHCClass I expressed on tumor cells and the TCR of
TILs, which interferes with the speciﬁc recognition and killing
of tumor cells.23-25,40 Reactive nitrogen intermediates can also
modify chemokines such as CCL2, preventing the recruitment
of tumor-speciﬁc lymphocytes.41 TAMs interfere with T-cell
function in other ways as well. Although more associated with
M1 TAMs and MDSCs, NO is another agent produced by
TAMs that can directly interfere with T-cell activation and
proliferation by reversibly blocking signaling through the IL-2
receptor.19-22,42
In addition to inhibiting effector TILs,M2TAMs can directly
inhibit and even kill effector TILs. A potential mechanism is
through direct cytotoxicity of effector TILs by engagement of
the PD-1 receptor with its ligands PL-L1 and PD-L2, which are
expressed by TAMs. M2 TAMs can inhibit the cytotoxic
antitumor effector functions of TILs through production of
the anti-inﬂammatory cytokines IL-10 and TGF-β. These
cytokines also promote the development of Tregs and regu-
latory DCs (regDCs), both of which suppress antitumor
immunity through their own array of mechanisms. Further-
more, TAMs selectively recruit immunosuppressive Tregs to
the tumor microenvironment through the secretion of chemo-
kines such as CCL22.12-14,43
Although TAMs in most tumors tend to have an immuno-
suppressive M2 phenotype, it is worth noting that TAMs have
the potential to adopt M1 polarization, which are generally
thought to have an antitumor effect.28 M1 macrophages do
produce the proinﬂammatory cytokines IL-1β, TNF, IL-6, and
IL-12, which promote antitumor T-helper type 1 immune
responses and effector function of cytotoxic T lymphocytes
(CTLs) and NK cells. M1 TAMs also recruit T-helper type 1
cells through secretion of chemokines such as CXCL9 and
CXCL10.28 Furthermore, M1-polarized TAMs can kill tumor
cells directly through antibody-dependent cellular cytotoxicity
as well as TNF production.44,45 In fact, the antitumor effect of
M1 TAMs was initially proposed to explain a correlationbetween tumor regression and elevated NO production by
macrophages in murine tumors.46,47 This association holds
true in some human tumors in which elevated M1-M2 TAM
ratios correlate with improved clinical outcomes including
survival.48-50 However, not all evidence supports an antitumor
effect of M1 TAMs. NO synthase, one of the quintessential M1
gene products, depletes arginine, which suppresses T-cell
function, and generates NO and reactive nitrogen species,
which can further inhibit antitumor immunity and promote
tumor progression.51-53Dendritic Cells
DCs are monocytic myeloid-derived antigen-presenting cells
(APCs) in the tumor microenvironment that mediate both
priming and tolerizing antitumor T-cells.12-14 Like macro-
phages, DCs are a heterogeneous cell type with at least 5
subtypes, each functionally and sometimes anatomically dis-
tinct.54,55 Although there are experimental conditions that
provide evidence for the importance of just about every
subtype of DC in T-cell priming, the most important players
seem to be the CD11bþ CD11cþCD4CD8αþ subset, the
CD11bþCD11cþCD4CD8 monocyte-derived population,
and the plasmacytoid DCs.56 The major population in tumors
are monocyte-derived DCs, which endocytose tumor antigens
and transport them to the draining lymph nodes where they
prime antigen-speciﬁc CD4þ and CD8þ T-cells in concert
with CD8αþ DCs. Plasmacytoid DCs also have an important
role in cross-priming antitumor CD8þ T-cell responses. These
cells are factories for type I INF, which has been implicated as a
vital part of the immune response to tumors. As early as 1983,
it was observed that depletion of type I INF could enhance
tumor growth in mice.57 Type I INF was later identiﬁed as a
mediator of cancer immunosurveillance inmice and is essential
for radiation-induced cross-priming of tumor-speciﬁc CTLs by
its action on CD8αþ DCs.24,58-63
Analogous to the M1-M2 paradigm for macrophages, DCs
can adopt a regulatory phenotype that promotes T-cell anergy
and tolerance.15,64 These regDCs can be identiﬁed by their
surface markers CD11bhighCD11clowGR1, but in practice,
differentiating between TAMs and DCs can be difﬁcult, as
histologic appearance and surface markers can give divergent
or ambiguous results. Functionally, regDCs mediate T-cell
anergy by presenting antigen in the context of decreased
surface expression of costimulatory molecules and production
of the anti-inﬂammatory cytokines IL-4, IL-10, and IL-13. In
the Lewis lung carcinoma and B16 melanoma tumor models,
regDCs could suppress T-cell activation and proliferation in
response to stimulation with the mitogen concanavalin
A in vitro, and adoptive transfer of regDCs promoted the
formation of tumor metastases.65Polymorphonuclear Neutrophils
Polymorphonuclear granulocytes, or PMNs, are the most
abundant leukocytes and important mediators of acute
inﬂammation and protection against bacterial infection. The
M1-M2 dichotomy has been extended to PMNs, which can
Myeloid-Derived Cells in Tumors 21assume a spectrum of phenotypes anywhere from tumoricidal
(N1) to suppressive of antitumor immunity (N2).36,38,39
However, the data supporting this distinction in tumor-
associated neutrophils (TANs) are still inconclusive. Further-
more, TANs are often deﬁned as CD11bþLy6Gþ cells, which
conﬂates them with the immunosuppressive granulocytic
MDSCs (g-MDSCs), now considered a distinct population
from mature PMNs.66 Gene expression data support the
concept of a spectrum of maturation and expression level
of a similar gene proﬁle, with N1 TANs representing
activated PMNs and N2 TANs resembling g-MDSCs
that can mature into N1 TANs with the appropriate stim-
ulus.67 In essence, the distinction between N1 and N2 is
functional, with N1 deﬁned as proinﬂammatory and N2 as
immunosuppressive.
The biological signiﬁcance of TANs is still under inves-
tigation, and unlike MDSCs and tumor macrophages, it is not
clear whether PMNs are more proinﬂammatory or immuno-
suppressive in tumors.36 In some human cancers such as clear
cell renal carcinoma, esophageal carcinoma, gastric carcinoma,
and squamous cell carcinoma of the head and neck, TAN
number and density are prognostic factors that correlate with
poor clinical outcome.68-71 This ﬁnding is consistent with the
concept that TANs, macrophages, andMDSCs all share similar
tools for immune suppression, including ROS such as hydro-
gen peroxide and expression of iNOS for the depletion of
L-arginine and production of NO.72 Somewhat paradoxically,
in studies of PMNs in vitro, iNOS and ROS mediate tumor
cytotoxicity, which is in stark contrast to g-MDSC that use the
same means to suppress antitumor immunity, as described
later. These contrasting ideas have not been resolved exper-
imentally, but it may be a result of the anatomical location of
the cells and immune mediators.Myeloid-Derived Suppressor Cells
MDSC is a collective term to describe a heterogeneous
population of immature myeloid cells that have immuno-
suppressive properites.10,53,73-75 They are found in the
blood, lymphoid organs, and tumor microenvironment in
animals and patients with cancer. Although they are deﬁned
functionally by their ability to suppress immune responses,
they also can be distinguished by their expression of surface
markers. There are 2 general populations of MDSCs that
reﬂect the 2 lineages of myeloid cells: monocytic and
granulocytic.76,77 In mice, monocytic MDSCs (m-MDSC)
are CD11bþLy6ChighLy6G, in contrast to g-MDSC, which
are CD11bþLy6ClowLy6Gþ. Humans do not express a
marker homologous to Ly6C/G (Gr1). Instead, human
MDSCs are deﬁned as CD11bþCD14CD33þ, making it
impossible to distinguish betweenm-MDSCs and g-MDSCs
based on surface markers.78 Both populations of MDSCs
are prevalent in the lymphoid organs, peripheral blood, and
tumors of tumor-bearing animals, with m-MDSCs more
prevalent in the tumor microenvironment.
MDSCs in the serum and tumor correlate with poor clinical
outcomes in patients and mediate suppression of the anti-
tumor immune response in mice both by antigen-speciﬁc andnonspeciﬁc mechanisms.74,79 A mechanism shared between
TAMs and m-MDSCs—the predominant MDSC population
in tumors—is the expression of iNOS and arginase. In addition
to inhibiting T-cell function by depleting L-arginine, iNOS
generates NO, which inhibits signaling through the IL-2
receptor, interfering with T-cell activation and proliferation.
The fact that M1 TAMs, which overall support antitumor
immunity, also express iNOS is somewhat of a paradox,
but perhaps the immunosuppressive effect of iNOS in these
cells is overwhelmed by their other proinﬂammatory and
antitumor mediators. In addition to arginine depletion and
NO generation, m-MDSCs generate ROS and reactive nitrogen
species such as peroxynitritemediated by iNOS and arginase.80
Much like the ROS generated by TAMs, peroxynitrite
can modify the TCR of antitumor T-cells making them unable
to bind to their cognateMHC-peptide antigen when presented
by tumors and other APCs in the tumor.81 These reactive
nitrogen species can also modify chemokines making
them inactive and preventing the recruitment of antitumor
immune cells.
Myeloid MDSCs can also suppress antitumor immunity
indirectly. Like M2 TAMs, MDSCs generate the cytokines
IL-10 and TGF-β that can suppress antitumor TILs,
generate Tregs in the tumor, and convert DCs into a regulatory
phenotype.82 MDSCs can also recruit Tregs to tumors
in a TGF-β–independent pathway.83 The g-MDSCs havemany
of the same immunosuppressive mechanisms as m-MDSCs,
but they also generate ROS that, like reactive nitrogen species,
can modify the TCR of TILs through direct cell-to-cell
contact.84Effect of Ionizing Radiation on
Tumor Myeloid Cells
Ionizing radiation profoundly affects the tumor microenviron-
ment, including the myeloid cells in tumors. Data supporting
this havebeen reported frommanydifferent tumormodels using
a variety of dose and fractionation regimens and are summarized
in the Table. The data are so disparate, dependent on radiation
dose and tumormodel, that uponﬁrst glance it seemsdifﬁcult to
draw any conclusions about a consistent effect of radiotherapy
(RT) on tumor myeloid cells. However, close examination
reveals some patterns arising from the noise of variability.85
The data supporting an effect of RT on tumor myeloid cells can
be characterized broadly as causing the 5 following effects:
recruitment, removal, reorganization, repolarization, and re-
presentation, each ofwhichwill be explained inmore detail later.Recruitment
Recruitment of myeloid-derived cells to tumors is one of the
more consistent ﬁndings associated with RT. The recruited
cells are primarily M2 TAMs andMDSCs and usually promote
tumor growth and immune evasion. There is some human
data frompatients who underwent enucleation for recurrent or
persistent uveal melanomawith a history of radiation delivered
by brachytherapy. The mean dose delivered to the tumor apex
Table Studies Demonstrating and Effect of Radiation on Tumor Myeloid Cells
Ref Model Dose or Fx Myeloid Cell Effect of RT
86 Human uveal melanoma Brachytherapy
median 86 Gy
TAM Recruitment, up to 5 y after RT.
87 Human glioma Brachytherapy
minimum
60 Gy
TAM and
microglia
Recruitment,o1 mo and persistent for41 y.
88 Mouse Panc02 pancreas 20 Gy  3 TAM Recruitment, 50% increase on day 7. M2 polarized. Tumor
control improved in NF-κB/ mice.
89 Mouse TRAMP-C1
prostate, ALTS1C1,
and GL261
astrocytoma
25 Gy  1 TAM, PMN,
and G-MDSC
Reorganization, CD11blow/CD68þ TAMs in hypoxic regions,
CD11blow/F4/80þ TAMs between hypoxic and necrotic
regions. CD11bþGr1þ PMN/G-MDSC in necrotic areas.
Increase in CD11bþGr1þ cells (20%), no TAM increase.
Tumor model and tissue effects.
98 Mouse TRAMP-C1
prostate
25 Gy  1 TAM Recruitment, CD68þ TAMs to hypoxic areas.
4 Gy  15
100 Mouse TRAMP-C1
prostate
25 Gy  1 TAM Repolarization, M2 genes (Arg-1 and COX2) up within days,
lasting weeks. Adoptive transfer of these TAMs shows a
trend toward faster tumor growth.
4 Gy  15
92 Mouse RM-1, RM-9, and
Myc-CaP prostate
3 Gy  5 (mice) TAM and
MDSC
Recruitment, RT- ABL1 nuclear translocation- CSF-1
transcription and translation-MDSC and TAM
recruitment.
Human prostate Standard
deﬁnitive Tx
(humans)
Patients treated for prostate cancer have an increase in CSF-
1 after RT.
93 U251 human
glioblastoma xenograft
2 Gy  5 TAM and
MDSC
Recruitment, RT- vasculature damage- hypoxia-HIF-1
- SDF-1, binds to CXCR4, and recruits TAM/MDSC.
Blocking HIF-1 or SDF-1/CXCR4 prevents myeloid cell
recruitment and tumor.
15 Gy  1
95 Human 54A lung
xenograft
20 Gy  1 TAM, MDSC,
and CD11bþ
myeloid cells
Recruitment, RT induces SDF-1, recruits CD11bþF4/80þ
TAMs and CD11bþF4/80Gr1 myeloid cells. Blocking
CXCR4 abrogates recruitment and improves tumor control
after RT.
Mouse MCa8 mammary 15 Gy þ 6 Gy
tumor RT
15 Gy þ 6 Gy
Total Body RT
96 Mouse TUBO mammary 12 Gy  1 TAM, MDSC,
and PMN
Removal, no increase inMDSC3 and 10 d. RT increasedPD-
L1 on tumor and myeloid cells. RT þ PD-L1 antagonist
controlled tumor and inducedsystemic antitumor immunity.
Mouse MC38 colon
106 Mouse MC57G
ﬁbrosarcoma
10 Gy  1 TAM Re-presentation, RT- tumor Ag cross-presentation by
TAMs, required for tumor elimination by RTþCTL adoptive
transfer.
90 Human FaDu
hypopharynx xenograft
12 Gy x 1 CD11bþ
myeloid cells
Recruitment, RT recruits CD11bþ myeloid cells. Inhibiting
CD11b or CD18 inhibits RT-mediated myeloid cell
recruitment and improves tumor response to RT.Mouse LLC lung, MC38
colon, and SCCVII
15 Gy  1
20 Gy  1
107 Mouse MT1A2 mammary 20 Gy  1 CD11bþ
myeloid cells
Recruitment, model speciﬁc, primarily MMP-9þ.
Mouse RIF ﬁbrosarcoma MMP-9þ myeloid cells are important for tumor
vasculogenesis and growth after RT.
101 Mouse RT5 insulinoma 0.5-6 Gy  1 TAM Repolarization, M2-M1 by lower dose RT (r2 Gy) or
adoptive transfer of irradiated macrophages- iNOS-
recruits endogenous or adoptive transferred T-cells. Doses
42 Gy deplete TILs. RT 0.5-5 Gy to human pancreas
cancer increases TILs.
Human MeWo melanoma
xenograft
Human pancreas
91 Mouse B16-OVA
melanoma
15 Gy  1 DC, TAM, and
MDSC
Recruitment, DC, TAM, and MDSC.
3 Gy  5 Re-presentation andDC,andpossiblemacrophage, in TDLN.
105 MouseB16-D5melanoma 8.5 Gy  5 DC Re-presentation and exogenous DC cross-present host
tumor antigen. RT does not affect maturation.
104 Mouse B16-SIY
melanoma
20-25 Gy  1 DC Re-presentation, DC, and possible macrophage, in TDLN
108 Mouse B16 melanoma 15 Gy  3 DC Re-presentation and DC required for RT-induced cross-
priming
Abbreviations: MMP, matrix metalloproteinase; Ref, reference; SDF, stromal-derived factor; TDLN, tumor-draining lymph node.
R.E. Vatner and S.C. Formenti22
Myeloid-Derived Cells in Tumors 23in these patients was 86 Gy, which resulted in an inﬂux of
macrophages into the tumor and surrounding irradiated sclera,
an effect that persisted for years after RT.86 Similar long-lived
macrophage recruitment was observed in the brain in patients
treated with brachytherapy to a minimum dose of 60 Gy for
glioma.87 Histopathologic analysis was performed at autopsy,
ranging from 3 weeks to 5 years after treatment, and at all time
points CD68þ macrophages and microglia were observed in
the treated tissues and tumors around areas of necrosis, which
occurred inside the 72-Gy isodose line. In both of these
studies, parts of the tumors were treated with much higher
doses of RT owing to the dose distribution properties of
brachytherapy.
This recruitment of TAMs in response to RT is seen in a
variety of murine tumor models as well. Lewis lung carcinoma
implanted subcutaneously and treated with 5 daily fractions of
6 Gy develops an inﬂux of Arg-1þ F4/80þ macrophages at all
time points tested, from 3-14 days after treatment (Fig. 2).
Crittenden et al88 observed an inﬂux of TAM and MDSCs in a
transplantable model of pancreatic adenocarcinoma (Panc02)
and metastatic breast cancer (4T1) after treatment with 3
fractions of 20 Gy. Gene array analysis of the TAMs revealed an
increase in transcription ofM2-relatedmessenger RNAs,which
was dependent on nuclear factor-κB (NF-κB), with indirect
evidence thatM2TAMs increase radiation resistance of tumors,
as Panc02 tumors in NF-κB/ mice responded better to RT
than tumors grown in wild-type mice. In the TRAMP-C1Figure 2 Radiation therapy increases tumor-inﬁltrating myeloid cells:
subcutaneous tumors of Lewis lung carcinoma were irradiated with
6 Gy on 5 consecutive days and harvested at 3, 7, and 14 days after
treatment completion.Tumor-inﬁltratingCD11bþ/Arg-1þmyeloidcells
(A, sham) were increased in irradiated (B) at all time points. (Courtesy
of Dr Barcellos-Hoff.)model of prostate cancer, two-thirds of all stromal cells in
untreated tumors are TAMs and MDSCs, which increases to
85% after a single dose of 25 Gy. TAMs were the most
prominentmyeloid cell type, but the recruited cells in response
to RTwere primarily CD11bþGr1þMDSCs or PMNs.89 Using
a xenograft model with human FaDu nasopharyngeal cancer
cells implanted into mice, Ahn et al90 observed a 2-4-fold
increase in CD11bþ myeloid cells 1 day and 7 days after
treatment with a single fraction of 20 Gy. Administering a
monoclonal antibody against CD11b abrogated this myeloid
cell recruitment and improved the tumor response to a single
fraction of 12 or 20 Gy of RT, an effect also seen in an
immunocompetentmurinemodel of head andneck squamous
cell carcinoma, SCCVII. A similar improvement in tumor
control after RT (15 Gy) was seen using the Lewis lung
carcinoma and MC38 colon carcinoma models in a murine
host deﬁcient in CD11 and CD18 that has decreased recruit-
ment of myeloid cells to tumors. Lugade et al91 observed an
increase in tumor-inﬁltrating DCs in addition to TAMs after
treatment of B16-OVA tumors with either 5 daily fractions of
3 Gy or a single fraction of 15 Gy.
Two different mechanisms have been proposed to explain
myeloid cell recruitment to tumors in response to RT.
Using the RM-1, RM-9, and Myc-CaP murine models of
prostate cancer, Xu et al92 observed a 3-fold increase in
TAMs and MDSCs one week after treatment with 5 daily
fractions of 3 Gy, which correlated with increased serum
concentrations of the macrophage chemokine and growth
factor colony stimulating factor 1 (CSF-1). Blocking the CSF-1
receptor with a small molecule inhibitor prevented the RT-
induced recruitment of myeloid cells, suggesting an essential
role for CSF-1 in the myeloid response to RT. Investigating the
mechanism further, they found that a single fraction of 3 Gy
induced CSF-1 gene transcription in vitro, which was
enhanced by nuclear translocation of the ABL1 kinase where
it binds to the CSF-1 promoter, an effect that was abolished by
depleting the cells of ABL1 using small interfering RNA. These
data suggest that RT induces translocation of ABL1 into
the nucleus where it binds to the CSF-1 promoter, inducing
gene expression and production of CSF-1 by tumor cells,
which is responsible for the inﬂux of MDSCs and TAMs in
response to RT.
A separate mechanism for RT-induced TAM recruitment
was elucidated by the work of the Brown group.93 Using the
U251 xenograft model in athymic mice, they observed that a
single 15-Gy fraction of RT disrupts the tumor vasculature
inducing tumor hypoxia, which results in expression of the
hypoxia-inducible factor-1 (HIF-1) as determined by an in vivo
luciferase reporter. HIF-1 is known to stimulate secretion of
stromal-derived factor-1, which recruits myeloid-derived cells
by binding CXCR4.94 Blocking the activity of HIF-1 with a
small molecule inhibitor or by genetic knockdown, or inhibit-
ing the stromal-derived factor-1-CXCR4 interaction on mye-
lomonocytic cells abrogates the recruitment of macrophages to
the tumor microenvironment. Consistent with the ﬁndings
described earlier, preventing recruitment of TAMs improves
the tumor response to RT. These ﬁndings were supported by a
separate group studying the 54A human lung cancer xenograft
R.E. Vatner and S.C. Formenti24and MCa8 mouse mammary tumors treated with 20-21 Gy in
1-2 fractions.95
Removal
Although the preponderance of data supports a recruitment
effect of RT on tumor myeloid cells, there is a report of
TAM and MDSC depletion in response to RT. Deng et al96
recently demonstrated a decrease in number of MDSCs in the
TUBO mammary carcinoma and MC38 colon carcinoma
models 3 days after treatment with a single fraction of 12 Gy
when combined with anti-PD-L1 immunotherapy, an effect
that was not observed when tumors were treated with RT
alone. Depletion of MDSCs after combined treatment was
dependent on CD8þ T lymphocytes, and the number of
MDSCs increased when CD8þ T-cells were depleted.
Although Crittenden et al88,97 observed an increase in TAMs
and MDSCs in 4T1 and Panc02 tumors after treatment with 3
fractions of 20 Gy, they observed a profound decrease in
peripheral MDSCs after treatment. This ﬁnding seemingly
conﬂicts with the results of Xu et al92 albeit in a different tumor
model (prostate) and with a substantially lower dose of RT
(3 Gy  5 fractions) and may simply reﬂect the systemic
response to improved tumor control after treatment with such
a large dose of RT.
Reorganization
In addition to affecting the numbers ofmyeloid cells in tumors,
RT causes a reorganization of macrophages in tumors.
This work has mostly been performed by the Hong group,
who demonstrated that a single fraction of 25 Gy induces
regions of hypoxia and necrosis in multiple tumor models,
including 2 glioma models and a prostate cancer model.89,98
They found that CD11blow/CD68þ TAMs clustered in hypoxic
regions, CD11blow/F4/80þ TAMs clustered in between
hypoxic and necrotic areas, and CD11bþGr1þ PMNs/MDSCs
centered in necrotic regions of the tumor after RT. This
migration and segregation of TAMs was model dependent.
Myeloid cells in TRAMP-C1 prostate tumors and GL261
gliomas assumed this clustering even in the absence of RT,
whereas this reorganization only occurred after RT in the
ALTS1C1 glioma model. Furthermore, RT-induced reorgan-
ization of TAMs was dependent on tissue location in the
ALTS1C1 glioma model, with clustering of TAMs in intra-
cranial tumors dependent on RT, but independent of RT in
tumors grown intramuscularly. An explanation for these
ﬁndings is that reorganization of tumor myeloid cells is
dependent on necrosis andhypoxia. Reorganizationmayoccur
independently of RT in tumor models that have more
spontaneous necrosis and hypoxia, whereas tumors with
improved oxygenation may only develop hypoxia and sub-
sequent myeloid cell reorganization after RT.
Repolarization
Macrophages and other myeloid cells have a plastic phenotype
that is exquisitely sensitive to environmental stimuli, and there
are many reports that radiation can repolarize TAMs, usuallytoward an M2 phenotype.28 TAMs and other myeloid cells in
tumors have a phenotype that promotes tumor growth and
suppresses antitumor immunity, partially owing to factors
secreted by the cancer cells themselves.99 For example, in the
TRAMP-C1 prostate cancer model, 15 fractions of 4 Gy or a
single fraction of 25 Gy induced the M2 genes ARG-1 and
COX2 within days of RT, and the effect lasted for many
weeks.100 This effect was also reported in the Panc02 model
after 3 fractions of 20 Gy, which induced M2 genes and
proteins in an NF-κB dependent manner.88 Interestingly, in
the RT5 insulinoma pancreatic cancer model, and in MeWo
human melanoma xenografts, Klug et al101 recently reported
that lower doses of RT, from 0.5-2 Gy, polarized TAMs toward
an M1 phenotype with increased production of iNOS. This
repolarization by lower doses of RT facilitated both endoge-
nous and adoptively transferred lymphocyte recruitment to
tumors and resulted in an improved tumor control when a
single dose of RT was combined with adoptive transfer of
tumor-speciﬁc T-cells. Although this is in contrast to ﬁndings
using higher doses of RT, it is consistent with data from
experiments using these lower doses of RT on peritoneal
macrophages in vitro.102Re-presentation
As professional APCs, macrophages and DCs can ingest tumor
antigens and re-present them on the cell surface in the context
of MHC Class I and Class II after proteolytic processing.103
This is essential for priming tumor-speciﬁc CD4þ helper and
CD8þ cytotoxic T-cells, and the evidence suggests that RT
induces re-presentation of tumor antigens by myeloid cells.
A number of studies demonstrate increased re-presentation of
tumor antigens by DCs in the tumor-draining lymph nodes
after RT. In the B16-SIY and B16-OVAmelanoma models, RT
doses from 15-25 Gy, or 5 fractions of 3 Gy all increase the
number of APCs cross-presenting tumor-speciﬁc antigens in
the tumor-draining lymph nodes, which correlated with
increased priming of antitumor T-cell responses.91,104 When
exogenous DCs are therapeutically introduced into poorly
immunogenic B16-D5 tumors, RT (8.5 Gy 5 fractions) also
increases tumor antigen uptake and presentation as well as
cross-priming.105
Among myeloid cells in tumors, DCs are generally consid-
ered the heroes of the antitumor immune response, essential
for T-cell priming, liberated by RT from the suppressive and
tolerogenic tumor microenvironment. Macrophages, by con-
trast, are presented as villains (as the data suggest), but the
Schreiber group has reported that TAMs are actually essential
for effective tumor rejection by the immune system.106 Using a
murine sarcoma model, a single fraction of 10 Gy induces
TAMs to cross-present tumor antigens on MHC Class I, a
transient effect that peaks 2 days after RT and is undetectable 4
days after treatment. It is not clear whether this cross-
presentation by TAMs is stimulating the tumor-speciﬁc T-cells,
making them more effective at killing tumor cells, or if TAMs
must be eliminated and cross-presentation makes them better
targets for CTL killing. In either case, this is an interesting
ﬁnding and may help explain why combinations of
Myeloid-Derived Cells in Tumors 25immunotherapy and RT are less effective when the 2 treat-
ments are not given concurrently.Conclusion
Myeloid cells in the tumor microenvironment are important
modulators of the immune response to tumors. As described
elsewhere in this issue, RT can promote both local and
systemic antitumor immunity; however, myeloid-derived cells
in the tumor often counteract development of an effective
immune response. Depending on the dose, fractionation, and
tumor model system, RT can have either a protumor or
antitumor effect by recruiting, removing, repolarizing, and
reorganizing, and inducing antigen re-presentation using
myeloid-derived cells in tumors. Most effects of RT reported
in the literature involve the recruitment and repolarization of
tumor-promoting immunosuppressive cells, making depletion
of TAMs, MDSCs, and other myeloid cells in the tumor
microenvironment an attractive therapeutic approach to com-
bine with RT. However, caution is warranted as these treat-
ments may remove DCs and M1-polarized TAMs that are
essential for effective antitumor immunity.
Clearly there is more work to be done, and as we move
forward there are some questions that must be answered to
improve the clinical and therapeutic relevance of manipulating
these cells: What markers can speciﬁcally differentiate one
subset of TAM or DC or MDSC from another and are these
subsets biologically meaningful? What is the effect of radiation
dose and fractionation on tumor myeloid cells? Are the
experimentally convenient single high-dose treatments rele-
vant and is the radiobiology of low doses (o2 Gy) completely
different? If so, what is the dose-dependent trigger that affects
this distinction? Many of these questions will be more readily
addressed after testing whether the efﬁcacy of small molecule
inhibitors of TAM and MDSC recruitment affects the systemic
immune response generated by RT.
However, the main question is how the ﬁeld will move
forward with an ever-expanding appreciation of the complex-
ity of the tumor microenvironment, or even within a class
of cells as reviewed herein. One anticipates the need for
an integrated analysis of how radiation affects the tumor
as a system. Each cell type of the immune system interacts
with all the others and often changes in response to the
evolving signals of a dynamic tumor. A better understanding is
necessary of which cells are critical and when they are most
amenable to therapeutic intervention in conjunction with
radiation and thus achieve long-term beneﬁt by reigniting
tumor immunity.Acknowledgment
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